2025. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Moderate to Severe Scalp Psoriasis: The Association Between Patient-Reported and Clinician-Reported Outcomes at Week 16 in a Phase 3b/4 Multicenter, Randomized, Double-blinded, Placebo-controlled Study (PSORIATYK SCALP). SKIN The Journal of Cutaneous Medicine. 9, 2 (Mar. 2025), s528. DOI:https://doi.org/10.25251/skin.10.supp.528.